68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer.
作者： Elif Neslihan Akdemir , Murat Tuncel , Fadıl Akyol , Cenk Yucel Bilen , Dilek Ertoy Baydar
DOI: 10.1007/S00345-018-2460-Y
关键词: Androgen deprivation therapy 、 Biopsy 、 Positron emission tomography 、 Prostate 、 PET-CT 、 Prospective cohort study 、 Univariate analysis 、 PSA Velocity 、 Medicine 、 Nuclear medicine
摘要: BACKGROUND 68Ga-PSMA Positron Emission Tomography/Computerized Tomography (PET/CT) has shown promising results for the detection of recurrent prostate cancer (RPCa). However, diagnostic value this method is yet to be validated. The aim study was determine influence clinical and biochemical variables on rate PET/CT in patients with RPCa. METHODS This a prospective 121 who underwent 68Ga-PSMA-PET/CT conventional imaging (CI) Detection rates were analyzed correlated various such as Gleason score GS), androgen deprivation therapy (ADT), trigger PSA (tPSA), doubling-time (PSAdt) velocity (PSAv). RESULTS showed at least one focus pathological uptake 92/121 (76%) patients. Nodal metastases (in 47% patients) most common site disease followed by bones (36%) (32%). Out patients, 57 (47%) had only positive findings PSMA scan verified biopsy or follow-up. majority these lesion located lymph nodes (31/57, 54,5%), which below limit CT. Univariate analysis higher increasing tPSA, PSAv short PSAdt. Best cutoff PSAdt 0.5 ng/ml, 2.25 ng/ml/year 8.65 months, respectively. PSMA-PET/CT high grade tumors (GS > 7, 23.7% vs 76.3%) ADT during (76.3% 96%). In multiple logistic regression analysis, concurrent identified predictors 68Ga-PSMA-PET/CT. CONCLUSION useful re-staging RPCa improved performance compared CI detection. are
springer.com
sci-hub.se 参考文章(20)
Francesco Ceci, Christian Uprimny, Bernhard Nilica, Llanos Geraldo, Dorota Kendler, Alexander Kroiss, Jasmin Bektic, Wolfgang Horninger, Peter Lukas, Clemens Decristoforo, Paolo Castellucci, Stefano Fanti, Irene J. Virgolini, 68 Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 42, pp. 1284- 1294 ,(2015) , 10.1007/S00259-015-3078-6
A. Afshar-Oromieh, A. Malcher, M. Eder, M. Eisenhut, H. G. Linhart, B. A. Hadaschik, T. Holland-Letz, F. L. Giesel, C. Kratochwil, S. Haufe, U. Haberkorn, C. M. Zechmann, PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 40, pp. 486- 495 ,(2013) , 10.1007/S00259-012-2298-2
Fujiko Watt, Anna Martorana, Diana E. Brookes, Thu Ho, Elizabeth Kingsley, Denise S. O'Keefe, Pamela J. Russell, Warren D.W. Heston, Peter L. Molloy, A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1 Genomics. ,vol. 73, pp. 243- 254 ,(2001) , 10.1006/GENO.2000.6446
Ali Afshar-Oromieh, Eleni Avtzi, Frederik L. Giesel, Tim Holland-Letz, Heinz G. Linhart, Matthias Eder, Michael Eisenhut, Silvan Boxler, Boris A. Hadaschik, Clemens Kratochwil, Wilko Weichert, Klaus Kopka, Jürgen Debus, Uwe Haberkorn, The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 42, pp. 197- 209 ,(2015) , 10.1007/S00259-014-2949-6
Matthias Eder, Oliver Neels, Miriam Müller, Ulrike Bauder-Wüst, Yvonne Remde, Martin Schäfer, Ute Hennrich, Michael Eisenhut, Ali Afshar-Oromieh, Uwe Haberkorn, Klaus Kopka, Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer Pharmaceuticals. ,vol. 7, pp. 779- 796 ,(2014) , 10.3390/PH7070779
M. J. Evans, P. M. Smith-Jones, J. Wongvipat, V. Navarro, S. Kim, N. H. Bander, S. M. Larson, C. L. Sawyers, Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen Proceedings of the National Academy of Sciences of the United States of America. ,vol. 108, pp. 9578- 9582 ,(2011) , 10.1073/PNAS.1106383108
Ali Afshar-Oromieh, Christian M. Zechmann, Anna Malcher, Matthias Eder, Michael Eisenhut, Heinz G. Linhart, Tim Holland-Letz, Boris A. Hadaschik, Frederik L. Giesel, Jürgen Debus, Uwe Haberkorn, Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 41, pp. 11- 20 ,(2014) , 10.1007/S00259-013-2525-5
David Good, Paul Schwarzenberger, James A. Eastham, Robert E. Rhoads, Jay D. Hunt, Michael Collins, Mark Batzer, Chris Theodossiou, Jay K. Kolls, Sidney R. Grimes, Cloning and characterization of the prostate-specific membrane antigen promoter. Journal of Cellular Biochemistry. ,vol. 74, pp. 395- 405 ,(1999) , 10.1002/(SICI)1097-4644(19990901)74:3<395::AID-JCB8>3.0.CO;2-0
Samuel R. Denmeade, Lori J. Sokoll, Susan Dalrymple, D. Marc Rosen, Alyssa M. Gady, Debra Bruzek, Rebecca M. Ricklis, John T. Isaacs, Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate. ,vol. 54, pp. 249- 257 ,(2003) , 10.1002/PROS.10199
M. Eiber, T. Maurer, M. Souvatzoglou, A. J. Beer, A. Ruffani, B. Haller, F.-P. Graner, H. Kubler, U. Haberhorn, M. Eisenhut, H.-J. Wester, J. E. Gschwend, M. Schwaiger, Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy The Journal of Nuclear Medicine. ,vol. 56, pp. 668- 674 ,(2015) , 10.2967/JNUMED.115.154153